ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
IFITM3 Is Elevated in BAL and Plasma Following Infection in ICU Setting.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Interferon-induced transmembrane protein 3 (IFITM3) is an antiviral protein with emerging roles in regulating inflammatory pathways. Although much is known about the role of IFITM3 in mediating host antiviral defense, its contribution to systemic immune responses during critical infectious illnesses remains less understood. Here, we provide evidence that IFITM3 levels were significantly higher in cell free BAL fluid in septic patients with pulmonary infections and in circulating plasma extracellular vesicles (EVs) from critically ill septic patients compared to critically ill non-septic patients and healthy individuals. This study provides the first evidence of IFITM3's association with sepsis induced inflammatory responses and bacterial pulmonary infections, raising its potential as an agent of dysregulated immunity during systemic infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.